COST-EFFECTIVENESS STUDY IN PEDIATRIC ALLERGIC DISEASE COST MANAGING ASTHMA

Study for cost managing asthma was implemented in order to recognize cost-effectiveness in treatment for pediatric allergic disease. One month-treatment cost of asthma outpatient treated at medical office, general hospital and university hospital, the age of 0 to 20, was studied. In the study, total outpatient cost was ¥22, 000 including that, physician's fee was ¥6, 000-¥7, 000 (¥4, 000 decreased at hospital), drug fee for treatment was ¥600, prescription drug fee was ¥11, 000, prescription fee was ¥1, 800, laboratory test fee was ¥2, 700. The contents of prescribed drug cost were 30% for DSCG, 28% for anti- allergic agents, 24% for theophyllines, 7% for oral β2 stimulants, 4% for BDP, 2% for inhalant β2 and 5% for others. For prescription drug fee, the difference by institution or the age of a patient was not observed, 2-3 times-difference by a severity of asthma was observed. A major point to consider a decrease in cost managing asthma is that, whether or not strong antiinflammatory inhalant steroid would be applied to mild asthma group treatment, and a consideration for long-time adverse effect and drug dependence, should be judged.